[1] Turcu AF, Yang J, Vaidya A. Primary aldosteronism:a multidimensional syndrome[J]. Nat Rev Endocrinol, 2022,18:665-682. [2] Felizola SJA, Maekawa T, Nakamura Y, et al. Voltage-gated calcium channels in the human adrenal and primary aldosteronism[J]. JSBMB, 2014, 144: 410-416. [3] Ng H, SK, LY, et al. Mutated KCNJ5 activates the acute and chronic regulatory steps in aldosterone production[J]. J Mol Endocrinol, 2016, 57:doi:10.1530/JME-15-0324. [4] Ottolia M, John S, Xie Y, et al. Shedding light on the Na+/Ca2+ exchanger[J]. Ann NY Acad Sci, 2007, 1099:78-85. [5] Barrett PQ, Guagliardo NA, Bayliss DA. Ion channel function and electrical excitability in the zona glomeru-losa: a network perspective on aldosterone regulation[J]. Annu Rev Physiol, 2021, 83: 451-475. [6] Santana LS. Pathogenesis of primary aldosteronism: impact on clinical outcome[J]. Front Endocrinol, 2022, 13.doi:10.3389/fendo.2022.927669. [7] Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism[J]. Hypertension, 2002, 40: 897-902. [8] 王芬. 钙通道阻滞剂对醛固酮瘤的醛固酮分泌功能的影响[D] . 北京: 北京协和医学院, 201:43-46 [9] 周婷婷, 杨仕伟, 罗鹏伟, 等. 维拉帕米对KCNJ5突变型H295R细胞醛固酮分泌功能的影响[J]. 现代泌尿生殖肿瘤杂志, 2020, 12: 298-302. [10] 高寅洁, 禹松林, 尹逸丛, 等. 钙通道阻滞剂对原代培养醛固酮产生腺瘤细胞类固醇激素谱的影响[J]. 基础医学与临床, 2022, 42: 1656-1660. [11] Blaustein MP, Lederer WJ. Sodium/calcium exchange: its physiological implications[J]. Physiol Rev, 1999, 79: 763-854. [12] Nagy N, Tóth N, Nánási PP. Antiarrhythmic and inotropic effects of selective Na+/Ca2+ exchanger inhibition: what can we learn from the pharmacological studies[J]. Int J Mol Sci, 2022, 23: 14651.doi:10.3390/ijms232314651. |